enow.com Web Search

  1. Ads

    related to: newest test for prostate cancer
    • Patient Resources

      Download informative brochures for

      patients and caregivers.

    • About Us

      Understand how a PSMA PET scan may

      help with your treatment plan.

Search results

  1. Results from the WOW.Com Content Network
  2. New prostate cancer imaging shows ‘extremely encouraging ...

    www.aol.com/prostate-cancer-imaging-shows...

    Prostate cancer imaging developed by university researchers has shown “extremely encouraging” results in its first clinical trials. ... The new imaging test begins by injecting a commonly used ...

  3. New Urine Test for Prostate Cancer May Help Reduce ... - AOL

    www.aol.com/lifestyle/urine-test-prostate-cancer...

    Researchers found that the test had a 95% sensitivity for prostate cancer of grade group 2 or greater, and 99% for grade group 3 or greater. “It does look impressive and exciting.

  4. Charity calls for change to prostate cancer testing guidelines

    www.aol.com/charity-calls-change-prostate-cancer...

    To measure the impact of new scans and tests, researchers analysed data from more than 16,000 men referred with suspected prostate cancer in two NHS registries covering 16 hospitals.

  5. PCA3 - Wikipedia

    en.wikipedia.org/wiki/PCA3

    n/a Ensembl ENSG00000225937 n/a UniProt n a n/a RefSeq (mRNA) n/a n/a RefSeq (protein) n/a n/a Location (UCSC) Chr 9: 76.69 – 76.86 Mb n/a PubMed search n/a Wikidata View/Edit Human Prostate cancer antigen 3 (PCA3, also referred to as DD3) is a gene that expresses a non-coding RNA. PCA3 is only expressed in human prostate tissue, and the gene is highly overexpressed in prostate cancer ...

  6. Prostate cancer screening - Wikipedia

    en.wikipedia.org/wiki/Prostate_cancer_screening

    Prostate cancer antigen 3 is a urine test that detects the overexpression of the PCA3 gene, an indicator of prostate cancer. [32] [46] [47] [44] ConfirmMDx is performed on tissue taken during a prostate biopsy. The test identifies men with clinically significant prostate cancer who would benefit from further testing and treatment.

  7. STAMPEDE (clinical trial) - Wikipedia

    en.wikipedia.org/wiki/STAMPEDE_(clinical_trial)

    Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE) is a clinical trial investigating treatments for high risk or terminal prostate cancer. Recruitment started in 2005 and ended in 2022; as of January 2020, over 10,000 participants had joined the trial.

  1. Ads

    related to: newest test for prostate cancer